Running title : HIV Controllers Summary
Less than 0.5% of HIV-1 infected patients maintain viral load below the threshold of 1 detection by conventional assays for many years without antiretroviral therapy. These 2 patients are known as HIV controllers (HICs) and offer a unique opportunity to explore and 3 unravel efficient mechanisms of defense against HIV. An intense research effort has led to 4 identify viral and host factors that contribute to the control of viral replication. Although the 5 host factors appear to be the primary determinants for HIV control, different genomic, 6 transcriptomic and immunological profiles have been described in HICs. This supports the 7 existence of different mechanisms of control. We review here the most significant data in 8 the field, including our own work, in the light of a crucial question: whether the ability to 9 achieve and maintain the control of HIV replication is linked to genetic or immunological 10 features specific to HIC or can be induced by vaccine or therapeutic approaches in the 11 general population.
Introduction

1
The pathogenesis of HIV infection in humans depends on a balance of viral and host factors. 2 The fitness of the virus and the type of cell that it is able to infect may have an enormous 3 impact on the rate of progression to disease (1-3). The virus relies on numerous cellular 4 factors to complete its replication cycle, and it needs to altogether overcome intrinsic cell 5 factors that are devised to hinder viral replication (4-6). Moreover, the host mobilizes a 6 panoply of immune responses, both innate and adaptive, to counteract infection. A better 7 understanding of the intimate interactions between the virus and the host will undoubtedly 8 provide important clues in the search for an HIV vaccine and cure. Interestingly, in a few 9 patients, the host factors appear to have prevailed over the virus, as these patients are able 10 to naturally control viral replication, maintaining extremely low virus levels (7-11). These 11 patients are known as HIV controllers (HICs) and offer a unique opportunity to explore and 12 unveil efficient mechanisms of defense against HIV.
14
Clinical characteristics 15 Transitory control of infection may occur in up to ~7% of all HIV-infected patients (12). 16 However, in most of these patients, control of the infection does not last long and is lost 17 within less than 12 months. In contrast, once control of viremia has been maintained for at 18 least one year, the probability of these patients maintaining undetectable viral replication 19 for numerous years is increased. Overall, the frequency of these long-term HIV controllers is 20 low. Several epidemiological studies have estimated that these patients may represent 21 around 0.5% of the total population of HIV-infected patients (9, 13, 14). The definition of 22 HICs varies worldwide depending on the threshold of maximal viral replication that is used or Patients who will become HICs typically have a non-symptomatic primary infection and have 11 higher CD4+ T cell levels and lower plasma viral loads and reservoir levels in the blood 12 compared to those who will not achieve control of infection (12, 16 ). This suggests that 13 efficient mechanisms of control start acting soon after infection in most of these patients (9). 14 However, the control of infection in some particular cases is a progressive phenomenon that 15 may require several years to accomplish (9). What differentiates these late controllers from 16 early controllers remains unknown, but comparative studies may provide interesting insights 17 into the development and relative contribution of the different mechanisms that may 18 participate in establishing control of infection in HICs. Little information is available 19 regarding co-infections by other pathogens in HICs, but at least some of these patients 20 appear to be able to control or even clear hepatitis C infection (17, 18). recently reported that declining CD4+ T cell levels were observed in patients who had 10 experienced blips in their viral loads or had higher low-level viremia (13, 21). In contrast, for 11 some HICs, a viral blip has never been recorded over very long follow-up periods (13). These 12 patients maintain stable CD4+ T cell levels, and many have undetectable viral loads even 13 when using ultrasensitive techniques able to detect 1 RNA copy/ml of plasma (our However, high levels of immune activation are a rather common characteristic observed in 13 HICs and do not entirely explain the more profound loss of CD4+ T cell counts in the rare 14 cases presented above. The low levels of viremia in HICs are similar to those found in HAART-treated patients (19, 6 21, 32), and a median value of 2 copies/ml in a cohort of HICs has been reported (33). In 7 contrast, HIV-1 reservoirs are much smaller in HICs than in patients on HAART (7, 34, 35).
8
This discrepancy raises the question of whether plasma viruses in HICs originate from 9 reactivations of this decreased latent reservoir or correspond to ongoing viral replication. HICs showed a temporal evolution of viral genes (36, 37). Interestingly, genetic evolution 20 was primarily restricted to the plasma viruses and was rare in cell-associated viral 21 sequences. Gag and nef proviral clones appeared to be ancestral to the plasma clones and additional studies will be needed to clarify these issues. 
